These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22020735)

  • 41. Eribulin.
    Perry CM
    Drugs; 2011 Jul; 71(10):1321-31. PubMed ID: 21770478
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report.
    Leo L; Caputo F; Sarno AD; Garofano T; Andreozzi F; Massaro MG; Montesarchio V
    Future Oncol; 2015; 11(15 Suppl):27-30. PubMed ID: 26235262
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.
    Leo S; Arnoldi E; Repetto L; Coccorullo Z; Cinieri S; Fedele P; Cazzaniga M; Lorusso V; Latorre A; Campanella G; Ciccarese M; Accettura C; Pisconti S; Rinaldi A; Brunetti C; Raffaele M; Coltelli L; Spazzapan S; Fratino L; Petrucelli L; Biganzoli L
    Oncologist; 2019 Jun; 24(6):e232-e240. PubMed ID: 30413667
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Eribulin: rediscovering tubulin as an anticancer target.
    Jimeno A
    Clin Cancer Res; 2009 Jun; 15(12):3903-5. PubMed ID: 19509144
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer.
    Mani S; Swami U
    Drugs Today (Barc); 2010 Sep; 46(9):641-53. PubMed ID: 20967296
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients.
    Quaquarini E; Sottotetti F; D'Ambrosio D; Malovini A; Morganti S; Marinello A; Pavesi L; Frascaroli M
    Future Oncol; 2017 Apr; 13(11s):11-23. PubMed ID: 28481185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2-negative Metastatic Breast Cancer.
    Smith J; Irwin A; Jensen L; Tedesco K; Misir S; Zhu W; Almonte A; He Y; Xie R; Olivo M; O'Shaughnessy J
    Clin Breast Cancer; 2020 Apr; 20(2):160-167. PubMed ID: 31980406
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer.
    de Nonneville A; Sabatier R; Gonçalves A; Extra JM; Tarpin C; Launay S; Tassy L; Viens P; Rousseau F
    J Geriatr Oncol; 2018 May; 9(3):281-283. PubMed ID: 29174186
    [No Abstract]   [Full Text] [Related]  

  • 49. Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.
    Dell'Ova M; De Maio E; Guiu S; Roca L; Dalenc F; Durigova A; Pinguet F; Bekhtari K; Jacot W; Pouderoux S
    BMC Cancer; 2015 Oct; 15():659. PubMed ID: 26449988
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
    Towle MJ; Nomoto K; Asano M; Kishi Y; Yu MJ; Littlefield BA
    Anticancer Res; 2012 May; 32(5):1611-9. PubMed ID: 22593439
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice.
    Tanaka T; Ueno M; Nakashima Y; Chinen S; Sato E; Masaki M; Mogi A; Sasaki H; Tamura K; Takamatsu Y
    Thorac Cancer; 2017 Sep; 8(5):523-529. PubMed ID: 28741868
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical efficacy and safety assessment of eribulin monotherapy in patients with metastatic breast cancer - a single- institute experience].
    Hattori M; Fujita T; Sawaki M; Kondo N; Horio A; Ushio A; Gondo N; Idota A; Ichikawa M; Iwata H
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):737-41. PubMed ID: 23863649
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinical evaluation of eribulin mesylate for the treatment of metastatic breast cancer].
    Matsuzaki H; Tohnosu N; Yoshiwara C; Maruyama T; Tanaka H; Natsume T; Miyazaki A; Sato Y; Ohta T; Yamamoto Y; Aikawa M; Ohtsuka R; Yanagihara A; Iwata K; Shiratori T; Miyazawa Y
    Gan To Kagaku Ryoho; 2014 Apr; 41(4):455-9. PubMed ID: 24743360
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Eribulin: a new-generation antimicrotubule agent in lung cancer therapy.
    Thara E; Gitlitz BJ
    Future Oncol; 2014 Oct; 10(12):1913-24. PubMed ID: 25386810
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
    Cortes J; Montero AJ; Glück S
    Cancer Treat Rev; 2012 Apr; 38(2):143-51. PubMed ID: 21550727
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long response to eribulin in breast cancer: a case report.
    Borgonovo K; Petrelli F; Cabiddu M; Ghilardi M; Coinu A; Seghezzi S; Barni S
    Future Oncol; 2015; 11(15 Suppl):3-8. PubMed ID: 26235258
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study.
    Moscetti L; Mentuccia L; Vici P; Quadrini S; Sperduti I; Pizzuti L; Fabbri MA; Vaccaro A; Maugeri-Saccà M; Barba M; Sergi D; Zampa G; Gamucci T
    Future Oncol; 2017 Jul; 13(17):1517-1525. PubMed ID: 28429617
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Eribulin in advanced breast cancer: safety, efficacy and new perspectives.
    Garrone O; Miraglio E; Vandone AM; Vanella P; Lingua D; Merlano MC
    Future Oncol; 2017 Dec; 13(30):2759-2769. PubMed ID: 29219017
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eribulin rapidly reduces the aggressiveness of second primary breast cancer: a case report.
    Falco I; Stragliotto S
    Future Oncol; 2017 Apr; 13(11s):51-54. PubMed ID: 28481187
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy.
    Mougalian SS; Feinberg BA; Wang E; Alexis K; Chatterjee D; Knoth RL; Nero D; Miller T; Liassou D; Kish JK
    Future Oncol; 2019 Dec; 15(34):3935-3944. PubMed ID: 31660764
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.